TY - JOUR
T1 - Cockroach GABAB receptor subtypes
T2 - Molecular characterization, pharmacological properties and tissue distribution
AU - Blankenburg, S.
AU - Balfanz, S.
AU - Hayashi, Y.
AU - Shigenobu, S.
AU - Miura, T.
AU - Baumann, O.
AU - Baumann, A.
AU - Blenau, W.
N1 - Funding Information:
We thank Markus Thamm for helpful discussions, Marcus Holschbach (Research Center Jülich, INM-5) for providing γ-hydroxybutyric acid, and Erich Buchner for generously providing anti-synapsin. This research was supported by grants from the German Research Foundation BL 469/4 and the University of Potsdam .
Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2015/1
Y1 - 2015/1
N2 - γ-aminobutyric acid (GABA) is the predominant inhibitory neurotransmitter in the central nervous system (CNS). Its effects are mediated by either ionotropic GABAA receptors or metabotropic GABAB receptors. GABAB receptors regulate, via Gi/o G-proteins, ion channels, and adenylyl cyclases. In humans, GABAB receptor subtypes are involved in the etiology of neurologic and psychiatric disorders. In arthropods, however, these members of the G-protein-coupled receptor family are only inadequately characterized. Interestingly, physiological data have revealed important functions of GABAB receptors in the American cockroach, Periplaneta americana. We have cloned cDNAs coding for putative GABAB receptor subtypes 1 and 2 of P. americana (PeaGB1 and PeaGB2). When both receptor proteins are co-expressed in mammalian cells, activation of the receptor heteromer with GABA leads to a dose-dependent decrease in cAMP production. The pharmacological profile differs from that of mammalian and Drosophila GABAB receptors. Western blot analyses with polyclonal antibodies have revealed the expression of PeaGB1 and PeaGB2 in the CNS of the American cockroach. In addition to the widespread distribution in the brain, PeaGB1 is expressed in salivary glands and male accessory glands. Notably, PeaGB1-like immunoreactivity has been detected in the GABAergic salivary neuron 2, suggesting that GABAB receptors act as autoreceptors in this neuron. This article is part of the Special Issue entitled 'GABAergic Signaling in Health and Disease'.
AB - γ-aminobutyric acid (GABA) is the predominant inhibitory neurotransmitter in the central nervous system (CNS). Its effects are mediated by either ionotropic GABAA receptors or metabotropic GABAB receptors. GABAB receptors regulate, via Gi/o G-proteins, ion channels, and adenylyl cyclases. In humans, GABAB receptor subtypes are involved in the etiology of neurologic and psychiatric disorders. In arthropods, however, these members of the G-protein-coupled receptor family are only inadequately characterized. Interestingly, physiological data have revealed important functions of GABAB receptors in the American cockroach, Periplaneta americana. We have cloned cDNAs coding for putative GABAB receptor subtypes 1 and 2 of P. americana (PeaGB1 and PeaGB2). When both receptor proteins are co-expressed in mammalian cells, activation of the receptor heteromer with GABA leads to a dose-dependent decrease in cAMP production. The pharmacological profile differs from that of mammalian and Drosophila GABAB receptors. Western blot analyses with polyclonal antibodies have revealed the expression of PeaGB1 and PeaGB2 in the CNS of the American cockroach. In addition to the widespread distribution in the brain, PeaGB1 is expressed in salivary glands and male accessory glands. Notably, PeaGB1-like immunoreactivity has been detected in the GABAergic salivary neuron 2, suggesting that GABAB receptors act as autoreceptors in this neuron. This article is part of the Special Issue entitled 'GABAergic Signaling in Health and Disease'.
KW - Adenylyl cyclase
KW - Central nervous system
KW - G-protein-coupled receptor
KW - GABA receptor
KW - Periplaneta Americana
KW - Salivary gland
UR - http://www.scopus.com/inward/record.url?scp=84908432578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908432578&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2014.08.022
DO - 10.1016/j.neuropharm.2014.08.022
M3 - Article
C2 - 25242738
AN - SCOPUS:84908432578
SN - 0028-3908
VL - 88
SP - 134
EP - 144
JO - Neuropharmacology
JF - Neuropharmacology
ER -